

## EPV0390

## The Effects of a Chatbot-Based Interpretation Bias Modification on Early Adulthood Depression

J. Lee\* and D. Lee

Kangwon National University, Chuncheon, Korea, Republic Of

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1105

**Introduction:** Depression, particularly in early adulthood, presents a significant mental health challenge with far-reaching implications. Innovative approaches to address and alleviate depressive symptoms are of paramount importance in this context. One such approach involves the utilization of technology, specifically chatbot-based programs, to target specific cognitive biases associated with depression.

**Objectives:** The central objective is to empirically examine whether this program can effectively influence depressive mood and negative cognition in individuals grappling with depressive symptoms.

**Methods:** To ascertain the program's efficacy, participants were divided into two groups: the CBM-I group (n=20), which underwent interpretation bias modification training, and the Mood Check group (n=20), which served as a control and engaged in a simple mood-checking exercise. A battery of psychological measures was employed, including assessments of depression, interpretation bias, suicidal ideation, resilience, and attention control.

**Results:** Analysis results showed that the CBM-I group had a significant reduction in depression (PHQ-9, CES-D) compared to the Mood Check group in the post-measurement. Moreover, resilience (CD-RISC) and attention control (ACQ) significantly improved in the CBM-I group.

**Conclusions:** This research serves as a stepping stone towards a deeper understanding of how chatbot-based interventions can contribute to the management of early adulthood depression, offering new perspectives and possibilities in the realm of mental health support and treatment.

**Disclosure of Interest:** None Declared

## EPV0391

## Obesity and depression: Review on common neurobiological mechanisms and identification of potential drug targets.

J. R. Lopez<sup>1,2\*</sup> and R. Zaghi-Lara<sup>3</sup><sup>1</sup>Posgrado de psiquiatría, Universidad de San Carlos de Guatemala;<sup>2</sup>President, Asociación Psiquiatría de Guatemala and <sup>3</sup>CIGua, Comunidad de Investigación de Guatemala, Guatemala, Guatemala

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1106

**Introduction:** This review aimed to identify common pathophysiological mechanisms that exist between depression and obesity, as well as pharmacological strategies used in clinical trials and animal models. It is necessary to carry out larger studies that integrate the multiple neurobiological processes of these phenomena and the search for therapeutic targets that affect these pathways.

**Objectives:** Conduct a literature review on the common neurobiological aspects that exist between depression and obesity. Compare pharmacological and therapeutic strategies in the management of depressive patients by means of common neurobiological mechanisms.

**Methods:** We used the Pubmed search engine to search for the keywords: ((depression and obesity) OR (common pathways for depression and obesity) OR (therapeutic targets for depression and obesity) OR (neurobiology of depression and obesity) OR (treatments for depression and obesity)) Once the predefined screening was carried out, 68 studies were identified. 54 articles were left for review and analysis. At the end of the review, 25 studies were discarded, including 29 studies with relevance to the objectives described in the study. These articles were selected when they provided information with adequate, concrete and specific reasoning towards the scientific and methodological elements of the review.

**Results:**

**Table 1:** Findings related to the NEGR1 gene and its involvement in processes associated with alterations associated with depression and obesity.

**Table 2:** Findings of inflammation associated with depression and obesity in clinical trials and animal models.

**Image:**

AUTHORS	STUDY SUBJECTS	FINDS
Lee et al. (2012)	Mouse deficient NEGR1 constitutive line and mutagenic ENU line with loss-of-function mutation (Negr1-187N)	Expression analyses confirmed the brain-specific distribution of NEGR1, strong expression in the hypothalamus. In vitro assays demonstrated NEGR1 promoted cell adhesion and neurite growth of hypothalamic neurons.
Carboni et al. (2020)	FSL Rats	Antidepressant treatments were able to influence the Negr1-Fgfr2 pathway and support the hypothesis that Negr1-mediated modulation of neuronal plasticity is activated by antidepressant treatment.

**Image 2:**

AUTHORS	OBJECTIVE OF THE STUDY	SUBJECT STUDIO	FINDS
Visser et al. (1999)	Assessment of overweight and obesity associated with low-grade systemic inflammation as measured by C-reactive protein level	16,616 non-pregnant men and women aged 17 years or older.	Elevated CRP level of 0.22 mg/dL or higher and a clinically elevated stricter CRP level of more than 1.00 mg/dL. A higher BMI is associated with higher concentrations of CRP, suggesting a state of low-grade systemic inflammation in overweight and obese individuals.
Capuron et al. (2008)	Relationship between MS and depressive symptoms in a population of 323 male twins, using the Beck Depression Inventory (BDI) and analyzing plasma CRP and IL-6 levels	323 male twins, with and without MS and free of symptomatic cardiovascular disease, drawn from the Vietnam Era Twin Registry.	MS is associated with a higher depressive symptomatology characterized mainly by neurovegetative traits. Inflammation is a determinant of depressive symptoms in people with MS.
You et al. (2011)	Detecting depression-like behavior in a rat animal model induced swelling in the spleen and brain by CMS	Wistar Rats	High expression of pro-inflammatory cytokines IL-1 $\beta$ , TNF- $\alpha$ and IL-6, and low expression of anti-inflammatory cytokines TGF- $\beta$ and IL-10.
Soto et al. (2018)	To evaluate behaviors and insulin action in the brains of diet-induced obesity (DIO) mice with and without antibiotic treatment.	Male mice C57BL/6J.	Decreased BDNF mRNA in hippocampus and hypothalamus of stressed rats. OID mice exhibit insulin resistance in the brain, depression-like behaviors, and anxiety, and these improve with antibiotic treatment.

**Conclusions:** Alterations in the NEGR1 gene, inflammatory markers, HPA axis and microbiota demonstrate multiple pathophysiological mechanisms in the clinical pictures associated with obesity and depression.

Infliximab, pioglitazone, ondansentron, BVT.2733 and palmitoylethanolamide showed anti-inflammatory regulatory effects with reduction in depressive symptoms and multiple anti-inflammatory markers.

Animal models for obesity and depression present ample and reliable evidence regarding the use of drugs that direct their

therapeutic profile towards the pathophysiological mechanisms involved in pathologies involving depressive and metabolic disorders.

**Disclosure of Interest:** None Declared

## EPV0394

### Effects of light therapy in the anxious-depressive clinic

M. T. Gonzalez Salvador<sup>1\*</sup>, R. Gutierrez-Labrador<sup>2</sup>,  
M. I. C. Gómez-Ulla<sup>1</sup> and A. I. de la Puente<sup>1</sup>

<sup>1</sup>Psiquiatria, Hospital Universitario Puerta de Hierro and <sup>2</sup>Psiquiatria, Hospital Universitario Infanta Sofia, Madrid, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1107

**Introduction:** Major depressive disorder (MDD) is defined as a mental disorder of multifactorial etiology, which presents with mood disturbance, mainly sadness associated with loss of interest or pleasure. Light therapy (LT) is a therapeutic intervention consisting of daily exposure to a light source. This study aims to evaluate the effects of LT on anxious-depressive symptomatology and sleep in a sample of patients diagnosed with depression.

**Objectives:** This study aims to evaluate the effects of LT on anxious-depressive symptomatology and sleep in a sample of patients diagnosed with depression.

**Methods:** Prospective case-control study, in which the cases are outpatients diagnosed with MDD and the controls are healthy individuals. Both groups underwent LT sessions and were assessed by means of validated scales, anxiety and depression symptoms before and after LT sessions, as well as changes in sleep patterns through a sleep measuring device.

**Results:** 11 cases and 18 controls were included in the study. Of the participants, 62.1% were female and 37.9% were male. The mean age of the sample was 54.03 ± 11.55 years. There were significant case differences in the pre and post LT scores of the depression scale. There were no significant differences in the changes in superficial, deep and total sleep and in the anxiety scale scores.

**Conclusions:** In the sample analysed, LT has significant effects on the cases at the level of the depression scale.

**Disclosure of Interest:** None Declared

## EPV0395

### Esketamine new tool for resistant depressive disorder. About a case

M. Valverde Barea\*, C. Mata Castro, P. Vargas Melero and A. España Osuna

Psychiatry, H.U. Jaén, Jaén, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1108

**Introduction:** Depressive disorders represent the main cause of disability in the world, due to its prevalence, its impact on the patient's quality of life and its role as one of the main risk factors for suicide. Current antidepressant treatments can take weeks to take

effect and months to achieve response and remission. It is estimated that up to 30% of patients with major depressive disorder (MDD) are resistant to antidepressant treatment, in addition, approximately 30-45% of patients with depression do not achieve an adequate response to the first antidepressant treatment. According to the STAR\*D study, the more lines of treatment are required, the lower remission rates are estimated, as well as higher relapse rates during the follow-up phase. With the appearance of intranasal dosage esketamine allows the release directly to the central nervous system, the mechanism of action of esketamine is based on the antagonism of the NMDA receptor, which entails the modulation of the excitatory transmission of glutamate and the release of BDNF, activating neurotrophic signaling and synaptogenesis.

**Objectives:** The objective is to expose the response after treatment with intranasal esketamine in a case of resistant depression.

**Methods:** A 55-year-old female patient, diagnosed with resistant recurrent depressive disorder. The patient had undergone treatment with different therapeutic lines with antidepressants, and potentiators with antipsychotics, observing little response in the current episode, for which reason we evaluated the indication of intranasal Esketamine. Scales: MADRS (Montgomery Asberg Depression rating scale) =37, Hamilton Depression Scale=25, PHQ-9=20, indicating severe depression.

**Results:** After starting treatment with intranasal esketamine, an early response was observed. After the first month of treatment, mild depression was scored at MADRS=10 and moderate depression at Hamilton=14, PHQ-9=12, and at week 14 of treatment, it was scored mild depression in both MADRS and Hamilton. Intranasal 56mg esketamine plus 20mg escitalopram, 30mg mirtazapine and 5mg aripiprazole.

**Conclusions:** Intranasal esketamine offers a rapid reduction in depressive symptoms maintained over time, reducing the risk of relapse and with a favorable tolerability profile, so its use in depression resistant to treatment presents a great advance.

**Disclosure of Interest:** None Declared

## EPV0397

### Cold water swimming as an add-on treatment for depression: a feasibility study

P. Hjorth<sup>1\*</sup> and M. R. V. Rasmussen<sup>2</sup>

<sup>1</sup>Psychiatry, Psychiatric Department, Vejle. Mental Health Services, Region of Southern Denmark, University Hospital of Southern Denmark. Institute of Regional Health research, University of Southern Denmark, Odense, Denmark and <sup>2</sup>Psychiatry, Vejle Psychiatric hospital, Vejle, Denmark

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.1109

**Introduction:** In Denmark, 14% of patients with depression develops treatment resistant depression (TRD) after the first hospital contact. Explanations for TRD include lack of clinical effect of pharmacological treatment and reluctance to treatment due to price, discomfort, and unacceptable side effects. Cold water swimming (CWS) describes swimming outdoors during the winter season in cold to ice-cold water on a regular basis. Many winter swimmers believe that exposure to cold water is beneficial for their health. However, evidence of health effects